LAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell ...

The MarketWatch News Department was not involved in the creation of this content. -- Catumaxomab Is the Only Approved Drug Therapy for Malignant Ascites, a Rare and Debilitating Complication of ...

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell ...

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature ...

Weight management following endometrial cancer treatment: A pilot trial to evaluate the efficacy of the profile by Sanford program. The GET FIT trial (NCT01635413): A randomized controlled trial of ...

O-glicosylation alterations of proteins in gastric carcinoma. Background: Peritoneal metastasis is considered to develop from carcinoma cells detached from the serosal surface of the primary site and ...

The first bispecific antibody to win regulatory approval is about to make a comeback 10 years after being taken off the market in Europe for commercial reasons. Catumaxomab, then called Removab, and ...

In a recent study published in Nature Medicine, researchers developed a deep-learning approach for tumor origin differentiation using cytological histology (TORCH), recognizing malignancy and ...

MAY 9, 2025, NEW YORK – A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies. Led by Ludwig ...

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies. Led by Ludwig Princeton's Lydia Lynch ...